Proactive Investors - Run By Investors For Investors

Novogen Limited drug could improve effectiveness of chemotherapy in children

Novogen Limited drug could improve effectiveness of chemotherapy in children

Novogen Limited (ASX:NRT, NASDAQ:NVGN) has completed a pre-clinical in vivo proof of concept study demonstrating its Anisina drug has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.

The anti-tropomyosin drug significantly improved the efficacy of standard of care microtubule targeting compound, vincristine, in an animal model of neuroblastoma.

It shows that animals can be dosed with a proprietary formulation of Anisina in combination with the standard of care and recapitulate in an animal model of neuroblastoma the same effect as observed in the test tube.

Neuroblastoma is a cancer that is most frequently observed in the young with more than 90% of diagnoses occurring in children under 5 years of age.

It is considered to be the most common solid tumour in children outside the brain.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full NRT profile View Profile

Novogen Ltd Timeline

Newswire
August 05 2015

Related Articles

1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
Hep C
November 22 2018
The company made positive operational progress in the year to June 30.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use